CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing a drug that targets the High mobility group box 1 protein (HMGB1) for stroke treatment. This candidate drug aims to provide neuroprotection beyond the current treatment window, addressing a significant unmet need in stroke care.
The scope of the project is to generate a candidate drug targeting the inflammatory mediator High mobility group box 1 protein (HMGB1) to be used in treatment of stroke.
The candidate drug will be validated in animal models, characterized and optimized for subsequent clinical development.Stroke remains a leading cause of death and disability throughout the world.
Within EU, more than 500 000 persons die of stroke each year.
Of those surviving stroke, 50% are left with physical or cognitive impai…
KAROLINSKA INSTITUTET
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Solna
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Italy, Milano
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, Liverpool
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Italy, Milano
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
